Endo International | ENDP - Srodki Pieniężne I Ekwiwalent



Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 5.23B 400M 2025-12
Amarin USD 122.8M 25.08M 2025-09
ANI Pharmaceuticals USD 285.58M 22.98M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Coherus Biosciences USD 88.88M 14.47M 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
Heron Therapeutics USD 43.07M 26.55M 2025-09
Hikma Pharmaceutical USD 236M 48M 2025-06
Ligand Pharmaceuticals USD 174.93M 489.59M 2025-12
Merck USD 18.17B 10.16B 2025-09
Novartis USD 9.56B 2.9B 2025-09
Pacira USD 158.54M 10.96M 2025-12
Perrigo USD 432.1M 22.1M 2025-09
Pfizer USD 1.34B 295M 2025-09
Phibro Animal Health USD 55.49M 17.28M 2025-12
Supernus Pharmaceuticals USD 151.37M 6.66M 2025-09
Takeda JPY 654.94B 26.55B 2025-12
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Xeris Pharmaceuticals USD 91.6M 32.32M 2025-09
Zoetis USD 2.08B 649M 2025-09